2021
438 The Efficacy of Measles, Mumps, Rubella (MMR) Vaccination in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT)
Schiffer M, Perreault S, McManus D, Ruggero M, Topal J, Seropian S, Bar N. 438 The Efficacy of Measles, Mumps, Rubella (MMR) Vaccination in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT). Transplantation And Cellular Therapy 2021, 27: s362-s363. DOI: 10.1016/s2666-6367(21)00464-4.Peer-Reviewed Original Research
2015
Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders
Branagan A, Duffy E, Boddupall C, Albrecht R, Zhang L, Verma R, Cooper D, Seropian S, Parker T, Yao X, Ferencz T, Dhodapkar M. Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. Blood 2015, 126: 3058. DOI: 10.1182/blood.v126.23.3058.3058.Peer-Reviewed Original ResearchHigh-dose influenza vaccineHigh-dose vaccinePlasma cell disordersNovel vaccination strategiesProtective HAI titersCell-mediated immunityMultiple myeloma patientsNovel vaccine strategiesInfluenza vaccineVaccination strategiesSignificant unmet needInfluenza vaccinationHAI titersPCD patientsCell disordersFlu seasonSecondary endpointsSeroprotection ratesDose vaccineMyeloma patientsVaccine strategiesFlu infectionUnmet needInfection rateGrade 2 adverse events
2006
Outpatient high‐dose melphalan in multiple myeloma patients
Kassar M, Medoff E, Seropian S, Cooper DL. Outpatient high‐dose melphalan in multiple myeloma patients. Transfusion 2006, 47: 115-119. PMID: 17207239, DOI: 10.1111/j.1537-2995.2007.01073.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmbulatory CareAnti-Bacterial AgentsAntibiotic ProphylaxisAntineoplastic Agents, AlkylatingBacteremiaCeftriaxoneDose-Response Relationship, DrugFeverHospitalizationHumansIncidenceLength of StayMelphalanMiddle AgedMultiple MyelomaNeutropeniaRetrospective StudiesStaphylococcal InfectionsStem Cell TransplantationConceptsHigh-dose melphalanOnset of neutropeniaPrimary care providersOutpatient settingMean durationPeripheral blood progenitor cell infusionGeneral outpatient settingProgenitor cell infusionTreatment-related mortalityMultiple myeloma patientsUse of ceftriaxoneApparent beneficial effectTransplant episodesMost patientsCell infusionFebrile patientsMedian timeMyeloma patientsRandomized trialsDecreased riskOutpatient therapyAmbulatory therapyOutpatient treatmentNeutropeniaCare providers
2003
A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents
Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, Cooper DL. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplantation 2003, 32: 1113-1117. PMID: 14647264, DOI: 10.1038/sj.bmt.1704286.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCombined Modality TherapyCyclophosphamideDatabases, FactualDexamethasoneDoxorubicinFemaleFeverGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansLeukapheresisMaleMiddle AgedMultiple MyelomaNeutropeniaPeripheral Blood Stem Cell TransplantationRetrospective StudiesTransplantation, AutologousVincristineConceptsMultiple myelomaEnough stem cellsCells/Autologous stem cell rescueFever/neutropeniaG-CSF beginningStem cell rescueHigh-dose chemotherapyPotential transplant candidatesMultiple myeloma patientsStem cell collectionStem cell toxicityStem cellsAggressive chemotherapyInitial therapyTransplant candidatesAgent therapyConsecutive patientsExcessive morbidityMyeloma patientsCell mobilizationCell rescuePatientsG-CSFCell collection